drugset / Trial / NCT03710863
Safety and Tolerability of Oral CM082 in Patients With wAMD
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Intermittent Oral Dosing of CM082 tablets in Chinese Patients With wAMD.
Timeline
- Start
- 2018-11-22
- Primary completion
- 2022-01-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM082 | Unknown | 25 mg | Oral |
| Subject | CM082 | Unknown | 50 mg | Oral |